Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary AngioedemaGlobeNewsWire • 11/08/25
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline TroubleZacks Investment Research • 11/07/25
Intellia Therapeutics Crashes After A Patient In Its Pivotal Study DiesInvestors Business Daily • 11/07/25
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall StreetThe Motley Fool • 11/07/25
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/06/25
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%The Motley Fool • 11/02/25
Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z TranscriptSeeking Alpha • 10/27/25
Intellia pauses late-stage trials of gene-editing treatment after serious liver eventReuters • 10/27/25
Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)GlobeNewsWire • 10/27/25
Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment OutlookSeeking Alpha • 10/24/25
Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?Zacks Investment Research • 10/20/25
Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?Zacks Investment Research • 10/09/25
Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 10/08/25
Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's What You Should KnowZacks Investment Research • 10/08/25
Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 10/08/25
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with PolyneuropathyGlobeNewsWire • 09/25/25
Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy ThesisSeeking Alpha • 09/19/25
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock UpZacks Investment Research • 09/19/25
Strength Seen in Intellia Therapeutics (NTLA): Can Its 29.8% Jump Turn into More Strength?Zacks Investment Research • 09/19/25
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary AngioedemaGlobeNewsWire • 09/18/25